Abbott Laboratories ( (ABT) ) has released its Q2 earnings. Here is a breakdown of the information Abbott Laboratories presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Abbott Laboratories is a global healthcare company that develops and markets a wide range of medical devices, diagnostics, branded generic medicines, and nutritional products, serving over 160 countries. In its second-quarter 2025 earnings report, Abbott announced a 7.4% increase in reported sales and a 6.9% increase in organic sales, excluding COVID-19 testing-related sales. The company reported a GAAP diluted EPS of $1.01 and an adjusted EPS of $1.26, reflecting strong financial performance.
Key highlights from the report include a significant increase in sales across various segments, with Medical Devices showing a 13.4% growth, driven by products like FreeStyle Libre and AVEIR. The Nutrition segment also saw growth, particularly in Adult Nutrition, while the Diagnostics segment experienced a decline due to reduced COVID-19 testing sales. Abbott’s operating margin improved, with a reported gross margin of 52.7% and an adjusted margin of 57.0%.
Strategically, Abbott completed the enrollment for its FlexPulse U.S. IDE trial and received FDA approval for its Tendyne transcatheter mitral valve replacement system. The company also announced plans to build a new cardiovascular device manufacturing facility in Georgia. These developments underscore Abbott’s commitment to innovation and expansion in the healthcare sector.
Looking ahead, Abbott projects full-year 2025 organic sales growth of 7.5% to 8.0%, excluding COVID-19 testing-related sales, and an adjusted diluted EPS of $5.10 to $5.20. The company’s management remains optimistic about maintaining momentum into 2026, driven by continued product pipeline advancements and market expansion.